Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Down 87.6% in March

Lonza Group Ag (OTCMKTS:LZAGY) was the recipient of a significant decrease in short interest in March. As of March 13th, there was short interest totaling 3,903 shares, a decrease of 87.6% from the February 26th total of 31,431 shares. Based on an average daily volume of 149,464 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the shares of the stock are sold short. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 149,464 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

LZAGY has been the topic of several analyst reports. Zacks Research cut Lonza Group from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 4th. Royal Bank Of Canada upgraded shares of Lonza Group from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, February 11th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold”.

Lonza Group Price Performance

Shares of OTCMKTS:LZAGY traded up $0.47 during trading on Tuesday, hitting $60.13. 122,381 shares of the company’s stock were exchanged, compared to its average volume of 85,412. The company has a quick ratio of 1.77, a current ratio of 2.24 and a debt-to-equity ratio of 0.42. The firm has a 50-day moving average price of $66.74 and a two-hundred day moving average price of $67.56. Lonza Group has a 1-year low of $55.57 and a 1-year high of $73.85.

Lonza Group Company Profile

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.